We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$60.5M
Cap. Flow %
10.28%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 68.48%
2 Miscellaneous 18.06%
3 Technology 6.31%
4 Industrials 2.63%
5 Communication Services 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
76
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.25M 0.38%
+40,000
New +$1.6M
NDRM
77
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.23M 0.38%
+74,500
New +$1.93M
PRTA icon
78
Prothena Corp
PRTA
$435M
$2.17M 0.37%
+40,000
New +$2.13M
ALBO
79
DELISTED
Albireo Pharma Inc
ALBO
$2.13M 0.36%
+103,526
New +$2.12M
DOVA
80
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$2.12M 0.36%
+95,000
New +$2M
ORLY icon
81
CALL
O'Reilly Automotive
ORLY
$68.7B
$2.04M 0.35%
+1,500
New +$24.5K
TMO icon
82
Thermo Fisher Scientific
TMO
$244B
$2.04M 0.35%
11,688
+4,775
+69% +$802K
OBSV
83
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.98M 0.34%
231,497
+20,411
+10% +$152K
SGEN
84
DELISTED
Seagen Inc. Common Stock
SGEN
$1.86M 0.32%
36,000
– –
MRNS
85
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.82M 0.31%
332,855
– –
TJX icon
86
TJX Companies
TJX
$139B
$1.78M 0.3%
49,400
+4,000
+9% +$151K
ARDX icon
87
Ardelyx
ARDX
$873M
$1.76M 0.3%
345,000
– –
PRQR icon
88
ProQR Therapeutics
PRQR
$267M
$1.72M 0.29%
330,000
– –
SPNS
89
DELISTED
Sapiens International
SPNS
$1.65M 0.28%
147,306
– –
AKAO
90
DELISTED
Achaogen Inc
AKAO
$1.63M 0.28%
75,000
-125,000
-63% -$2.85M
TSEM icon
91
Tower Semiconductor
TSEM
$24.8B
$1.6M 0.27%
67,155
– –
SMMT icon
92
Summit Therapeutics
SMMT
$14.1B
$1.56M 0.27%
142,018
-5,432
-4% -$61.2K
FLEX icon
93
Flex
FLEX
$40.2B
$1.54M 0.26%
+125,402
New +$1.55M
PDSB icon
94
PDS Biotechnology
PDSB
$60.9M
$1.54M 0.26%
7,500
– –
WAB icon
95
Wabtec
WAB
$47.1B
$1.52M 0.26%
+16,600
New +$1.38M
VTVT icon
96
vTv Therapeutics
VTVT
$126M
$1.49M 0.25%
7,500
– –
MGNX icon
97
MacroGenics
MGNX
$262M
$1.42M 0.24%
81,200
– –
OEF icon
98
CALL
iShares S&P 100 ETF
OEF
$20.3B
$1.42M 0.24%
100
– –
MA icon
99
Mastercard
MA
$496B
$1.4M 0.24%
11,525
– –
RNTX
100
Rein Therapeutics
RNTX
$67.9M
$1.39M 0.24%
+6,250
New +$1.37M
2 3
4
5 6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management deployed $60.5M of net new capital in Q2 2017, opening 41 new positions and adding to 30 existing holdings. Its largest new stake was GSK: 360,000 shares worth $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 64% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Shire pic, an estimated $25.5M trimmed.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.